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Coll Cardiol 2013;61:723–7.REPLY: Lights and Shadows of Antiplatelet
Therapy in Primary Percutaneous Coronary
InterventionWe thank Lozano et al. for their thoughtful comments
on our ETAMI (Early Thienopyridine Treatment to
Improve Primary PCI in Patients With Acute Myocar-
dial Infarction) trial (1) and fully agree with their
statement that in antithrombotic therapy, there
should always be a balance between efﬁcacy and
safety. Our study has investigated the very acute
phase of primary percutaneous coronary intervention
(PCI) in ST-segment elevation myocardial infarction
(STEMI) in which a faster onset of action of a platelet
inhibition effect is desirable to reduce ischemic com-
plications of the procedure. In the recently published
ATLANTIC (A 30 Day Study to Evaluate Efﬁcacy and
Safety of Pre-hospital vs. In-hospital Initiation of
Ticagrelor Therapy in STEMI Patients Planned for
Percutaneous Coronary Intervention) trial, a very
early initiation of ticagrelor in the pre-hospital phase
leading to clinical relevant difference in platelet in-
hibition 1 h after PCI was associated with a reduction
in stent thrombosis compared with the same loading
dose started on average 31 min later in the hospital (2).
In addition, there are several reports linking inade-
quate platelet inhibition at the time of PCI to ischemic
complications, underscoring the importance of an
effective platelet periprocedural inhibition during
primary PCI (3). In the TRITON (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition With Prasugrel) trial, patients with
STEMI have especially beneﬁted from prasugrel
compared with clopidogrel without an increase
in bleeding complications (4). These results were
conﬁrmed by recent reports from real-life experience
of registries. Bleeding complications in TRITON
accumulated over time but were not statistically
different between clopidogrel and prasugrel in the
primary PCI group at 30 days as well as at 15 months
(4). The net clinical beneﬁt was clearly in favor of
prasugrel. The statement about a differential effect of
prasugrel between secondary and primary PCI in
STEMI is not correct, and this reference indicated no
statistical heterogeneity between the 2 groups (4).
This has been now well evaluated, and there is no
signiﬁcant interaction for the primary and secondary
endpoints and a consistent effect of prasugrel acrossall types of PCI performed in STEMI patients (5). The
numerical differences are related to the difﬁculties in
measuring periprocedural MI in primary PCI versus
secondary PCI and not related to the efﬁcacy of
prasugrel (5). The statement about contraindications
against prasugrel majorly relates to patients with prior
stroke, which is present in up to 3% of STEMI patients.
Elderly or patients with low body weight <60 kg might
be treated with the same loading dose of 60 mg and a
lower maintenance dose of 5 mg to reduce bleeding
complications.*Uwe Zeymer, MD
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Therapy Following
Anterior ST-Segment
Elevation Myocardial
InfarctionWe would like to commend LeMay et al. (1) for their
work addressing the important clinical conundrum
of whether to provide triple antithrombotic therapy
(TATT) for patients presenting apical akinesis/
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 7 , 2 0 1 5 Letters to the Editor
J U N E 2 0 1 5 : 1 0 0 1 – 6
1003dyskinesis following anterior ST-segment elevation
myocardial infarction. This study takes advantage of
a patient population with consistent follow-up within
the same regional health system, managed at a high-
volume academic center, and participating in a
detailed prospective clinical database. In reviewing
the report, however, we were left with a few ques-
tions; the answers to which might be of interest to
other readers.
First, it is not clear to us from our reading of the
paper how the propensity score was derived, for what
clinical parameter propensity was determined (i.e.,
propensity for TATT vs. propensity for net adverse
clinical events) (2), or how the propensity score was
used to determine the net adverse clinical events
odds ratio reported for warfarin therapy. Was this
also part of the inverse-probability weighting multi-
variable regression analysis?
Second, and somewhat related, it would seem,
from the data presented, that anticoagulation with
warfarin for apical dysfunction is the exception rather
than the rule at this particular institution, with fewer
patients treated and with TATT patients having more
apical dysfunction, worse ejection fractions, and a 3-
fold higher rate of cardiogenic shock. As such, we are
left to wonder whether this retrospective analysis
suffers from intractable confounding, which would
explain the apparent paradoxical increase in non-
hemorrhagic events in this group.
Finally, we would ask the authors to comment on
both the timing of adverse bleeding events prior to
hospital discharge (post-procedure vs. post-initiation
of warfarin) and the decision to include these in the
primary analysis. It would stand to reason that most
patients in this group did not have a therapeutic In-
ternational Normalized Ratio until the last day or 2 of
hospitalization. A “back of the envelope” calculation
suggests that the exclusion of in-hospital events
would make the difference in outcomes between the 2
groups considerably less dramatic. Would a land-
marked analysis from the time of discharge have also
achieved statistical signiﬁcance?*Brian J. Potter, MDCM, MSc
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Perils of Procedure-Based
Risk ScoresSherwood et al. (1) report that groups that perform
more high-risk percutaneous coronary interventions
have similar risk-adjusted mortality to those who
perform fewer. The data are interesting, but a number
of limitations preclude the ﬁnal conclusion that
adopting a more aggressive practice pattern will not
increase risk-adjusted mortality.
Subgroups do not have uniform risk. Patients in
cardiogenic shock have mortality rates that range
from 22% to 88% (2). Physicians preferentially treat
patients at the lower spectrum of risk and thus will
have lower observed mortality than predicted by risk
scores. At the same time, motivated practitioners
have an incentive to “up-code,” which artiﬁcially
inﬂates the estimated risk. The fact that in Sherwood
et al. (1), “high-risk” cases tended to have lower-
than-expected mortality is consistent with these
limitations.
The conclusion also assumes that risk-averse op-
erators are as adept as those who regularly perform
high-risk cases. One of the beneﬁts touted for public
reporting is that it directs higher-risk cases towards
superior operators (3).
A ﬁnal limitation is the exclusion of patients who
receive angioplasty at one site, but are then trans-
ferred to a different site. This excludes high-risk pa-
tients and procedural complications that might
signiﬁcantly alter the ﬁnal results.
These limitations were not present at a Canadian
regional care center, free of the medico-legal and
public reporting concerns of the United States. In this
setting, regional efforts to more aggressively treat
high-risk myocardial infarction patients led to an in-
crease in risk-adjusted mortality despite evidence for
preserved procedural quality (4).
This debate also distracts from the more important
issue. The real question is whether risk aversion re-
lated to public reporting results in public harm. This
